JNJ-5279 is under clinical development by Johnson & Johnson and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect JNJ-5279’s likelihood of approval (LoA) and phase transition for Autism took place on 09 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JNJ-5279 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

JNJ-5279 overview

JNJ-5279 is under development for the treatment of generalized anxiety disorder, autism spectrum disorder and neuropathic pain. It is administered orally in the form of tablet. It is an aryl piperazinyl urea. The drug candidate is a new molecular entity (NME), which acts as FAAH inhibitor. It was also under development for social anxiety disorder (SAD) and major depressive disorder with anxious distress.

Johnson & Johnson overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Quick View JNJ-5279 LOA Data

Report Segments
  • Innovator
Drug Name
  • JNJ-5279
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.